Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging

Noninvasive imaging technologies have the potential to enhance the monitoring and improvement of adoptive therapy with tumor-targeted T lymphocytes. We established an imaging methodology for the assessment of spatial and temporal distributions of adoptively transferred genetically modified human T cells in vivo for treatment monitoring and prediction of tumor response in a systemic prostate cancer model. Methods: RM1 murine prostate carcinoma tumors transduced with human prostate-specific membrane antigen (hPSMA) and a Renilla luciferase reporter gene were established in SCID/beige mice. Human T lymphocytes were transduced with chimeric antigen receptors (CAR) specific for either hPSMA or human carcinoembryonic antigen (hCEA) and with a fusion reporter gene for herpes simplex virus type 1 thymidine kinase (HSV1tk) and green fluorescent protein, with or without click beetle red luciferase. The localization of adoptively transferred T cells in tumor-bearing mice was monitored with 2′-18F-fluoro-2′-deoxy-1-β-d-arabinofuranosyl-5-ethyluracil (18F-FEAU) small-animal PET and bioluminescence imaging (BLI). Results: Cotransduction of CAR-expressing T cells with the reporter gene did not affect CAR-mediated cytotoxicity. BLI of Renilla and click beetle red luciferase expression enabled concurrent imaging of adoptively transferred T cells and systemic tumors in the same animal. hPSMA-specific T lymphocytes persisted longer than control hCEA-targeted T cells in lung hPSMA-positive tumors, as indicated by both PET and BLI. Precise quantification of T-cell distributions at tumor sites by PET revealed that delayed tumor progression was positively correlated with the levels of 18F-FEAU accumulation in tumor foci in treated animals. Conclusion: Quantitative noninvasive monitoring of genetically engineered human T lymphocytes by PET provides spatial and temporal information on T-cell trafficking and persistence. PET may be useful for predicting tumor response and for guiding adoptive T-cell therapy.

[1]  Z. Eshhar,et al.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Rosenberg,et al.  Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain , 1993, The Journal of experimental medicine.

[3]  R. Blasberg,et al.  Imaging the expression of transfected genes in vivo. , 1995, Cancer research.

[4]  J. Trapani,et al.  Expression in cytotoxic T lymphocytes of a single‐chain anti‐carcinoembryonic antigen antibody. Redirected Fas ligand‐mediated lysis of colon carcinoma , 1998, European journal of immunology.

[5]  V. Diehl,et al.  An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. , 1998, Cancer research.

[6]  V. Diehl,et al.  A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA , 1998, Gene Therapy.

[7]  P. Hand,et al.  Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. , 1999, Human gene therapy.

[8]  N. Bander,et al.  Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. , 1999, Neoplasia.

[9]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.

[10]  B. Seliger,et al.  Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 , 2001, The Journal of Immunology.

[11]  S. Forman,et al.  T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. , 2003, Blood.

[12]  Michel Sadelain,et al.  Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes , 2003, Nature Biotechnology.

[13]  R. Blasberg,et al.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  R. Blasberg,et al.  Cytoplasmically retargeted HSV1-tk/GFP reporter gene mutants for optimization of noninvasive molecular-genetic imaging. , 2003, Neoplasia.

[15]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[16]  Sanjiv S Gambhir,et al.  Quantitative imaging of the T cell antitumor response by positron-emission tomography , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Michel Sadelain,et al.  Targeting tumours with genetically enhanced T lymphocytes , 2003, Nature Reviews Cancer.

[18]  S. Forman,et al.  Specific Recognition and Killing of Glioblastoma Multiforme by Interleukin 13-Zetakine Redirected Cytolytic T Cells , 2004, Cancer Research.

[19]  E. Pamer,et al.  In vitro Stimulation with WT1 Peptide-Loaded Epstein-Barr Virus-Positive B Cells Elicits High Frequencies of WT1 Peptide-Specific T Cells with In vitro and In vivo Tumoricidal Activity , 2004, Clinical Cancer Research.

[20]  Vladimir Ponomarev,et al.  Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice , 2004, Cancer Research.

[21]  Sanjiv S Gambhir,et al.  Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[22]  Michel Sadelain,et al.  Targeted elimination of prostate cancer by genetically directed human T lymphocytes. , 2005, Cancer research.

[23]  J. Wolchok,et al.  Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination , 2005, International journal of cancer.

[24]  S. Rosenberg,et al.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. , 2005, Human gene therapy.

[25]  H. Heslop,et al.  Current status of genetic modification of T cells for cancer treatment. , 2005, Cytotherapy.

[26]  Sanjiv S Gambhir,et al.  Visualization of a primary anti-tumor immune response by positron emission tomography. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Larson,et al.  [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  S. Gambhir,et al.  Monitoring the Antitumor Response of Naive and Memory CD8 T Cells in RAG1−/− Mice by Positron-Emission Tomography1 , 2006, The Journal of Immunology.

[29]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[30]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[31]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[32]  S. Larson,et al.  Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  J. Sprent,et al.  Cytokines and T-cell homeostasis. , 2003, Current opinion in immunology.

[34]  V. Ponomarev,et al.  A Human-Derived Reporter Gene for Noninvasive Imaging in Humans: Mitochondrial Thymidine Kinase Type 2 , 2007, Journal of Nuclear Medicine.